ArticleHuman vaccines & immunotherapeutics2022

Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study.

Kandace L Amend et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.